4//SEC Filing
Townsend Adam J. 4
Accession 0001127602-23-012593
CIK 0001492422other
Filed
Apr 4, 8:00 PM ET
Accepted
Apr 5, 4:50 PM ET
Size
8.4 KB
Accession
0001127602-23-012593
Insider Transaction Report
Form 4
Townsend Adam J.
Chief Commercial Officer
Transactions
- Sale
Common Stock
2023-04-03$74.05/sh−5,000$370,250→ 75,995 total - Exercise/Conversion
Common Stock
2023-04-03$15.09/sh+5,000$75,450→ 80,995 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-04-03−5,000→ 287,500 totalExercise: $15.09Exp: 2028-11-15→ Common Stock (5,000 underlying)
Footnotes (2)
- [F1]This is a scheduled exercise and sale from an established 10b5-1 plan.
- [F2]This option was granted on November 16, 2018 and vests as to 25% of the shares underlying the options on the first anniversary of Mr. Townsend's date of hire, November 16, 2018, with the remaining 75% of the shares underlying the option vesting in equal monthly installments thereafter through the fourth anniversary of his date of hire, subject to continued service.
Documents
Issuer
Apellis Pharmaceuticals, Inc.
CIK 0001492422
Entity typeother
Related Parties
1- filerCIK 0001773588
Filing Metadata
- Form type
- 4
- Filed
- Apr 4, 8:00 PM ET
- Accepted
- Apr 5, 4:50 PM ET
- Size
- 8.4 KB